Filtered By:
Condition: Heart Failure
Infectious Disease: Hepatitis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 30 results found since Jan 2013.

Atherosclerosis on CT coronary angiography and risk of long-term cardiovascular events post liver transplantation
CONCLUSION: The standardized CAD-RADS classification on CTCA predicted the occurrence of cardiovascular outcomes following LT, with a potential to increase utilization of preventive cardiovascular therapies.PMID:37432891 | DOI:10.1097/LVT.0000000000000215
Source: Atherosclerosis - July 11, 2023 Category: Cardiology Authors: Thalys Sampaio Rodrigues Anoop N Koshy Paul J Gow Laurence Weinberg Benjamin Cailes Adam Testro Gerard Smith Han S Lim Andrew W Teh Ruth P Lim Omar Farouque Source Type: research

Interaction between SIRT1 and non-coding RNAs in different disorders
SIRT1 is a member of the sirtuin family functioning in the process of removal of acetyl groups from different proteins. This protein has several biological functions and is involved in the pathogenesis of metabolic diseases, malignancy, aging, neurodegenerative disorders and inflammation. Several long non-coding RNAs (lncRNAs), microRNAs (miRNAs) and circular RNAs (circRNAs) have been found to interact with SIRT1. These interactions have been assessed in the contexts of sepsis, cardiomyopathy, heart failure, non-alcoholic fatty liver disease, chronic hepatitis, cardiac fibrosis, myocardial ischemia/reperfusion injury, diab...
Source: Frontiers in Genetics - June 27, 2023 Category: Genetics & Stem Cells Source Type: research

Estimate of the prevalence of subjects with chronic diseases in a province of Northern Italy: a retrospective study based on administrative databases
Conclusions Despite the difficulty of having a unique definition of chronic disease, the prevalence obtained was coherent with the estimates reported by other national surveillance systems such as Passi and Passi d’Argento. Underestimates were observed when international comparisons were done; however, when we used less stringent definitions of chronic diseases, similar results were obtained.
Source: BMJ Open - June 19, 2023 Category: General Medicine Authors: Airoldi, C., Pagnoni, F., Cena, T., Ceriotti, D., De Ambrosi, D., De Vito, M., Faggiano, F. Tags: Open access, Public health Source Type: research

Child-Pugh Class B or C Liver Disease Increases the Risk of Early Mortality in Patients With Hepatitis C Undergoing Elective Total Joint Arthroplasty Regardless of Treatment Status
CONCLUSION: Patients with HCV and a Child-Pugh Class B or C at the time of elective TJA had substantially increased odds of death, regardless of liver function, cirrhosis, age, Model for End-Stage Liver Disease level, HCV treatment, and viral load status. This is similar to the risk of early mortality observed in patients with chronic liver disease undergoing abdominal and cardiac surgery. Surgeons should avoid these major elective procedures in patients with Child-Pugh Class B or C whenever possible. For patients who feel their arthritic symptoms and pain are unbearable, surgeons need to be clear that the risk of death is...
Source: Clinical Orthopaedics and Related Research - March 24, 2023 Category: Orthopaedics Authors: Kyle H Cichos Eric Jordan Kian Niknam Antonia F Chen Erik N Hansen Gerald McGwin Elie S Ghanem Source Type: research

Prevalent Multimorbidity Combinations Among Middle-Aged and Older Adults Seen in Community Health Centers
ConclusionsCHCs are increasingly seeing more complex multimorbidity patterns over time; these most often involve mental health morbidity and advanced cardiometabolic-renal morbidity.
Source: Journal of General Internal Medicine - January 28, 2022 Category: Internal Medicine Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
ConclusionsIn this population-based study, we did not identify an independent association between steatosis and fibrosis and CVD. Large prospective cohort studies are needed to provide a more definitive evidence on this topic.
Source: Frontiers in Endocrinology - July 26, 2021 Category: Endocrinology Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research

Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis.
CONCLUSION: The analysis of the French pharmacovigilance database cases allows to confirm an expected and monitored risk profile in the risk management plan for both drugs. Several signals have arisen, some of which will be investigated through a pharmacoepidemiology study. PMID: 33376005 [PubMed - as supplied by publisher]
Source: Therapie - December 13, 2020 Category: Psychiatry & Psychology Authors: Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E, et le réseau français des Centres régionaux de pharmacovigilance Tags: Therapie Source Type: research